FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068086148> ?p ?o ?g. }

• W2068086148 endingPage "91" @default.
• W2068086148 startingPage "80" @default.
• W2068086148 abstract "Endogenous androgens play a role in the development and progression of prostate cancer (PC), thus androgen suppression may offer an effective therapeutic strategy for this disease. Orteronel (TAK-700), 6-[(7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthamide, is a novel, non-steroidal, selective inhibitor of the 17,20-lyase activity of CYP17A – a key enzyme in the production of steroidal hormones – and is being developed as a therapy for PC. The purpose of this study was to elucidate the inhibitory activity of orteronel, in particular its specificity for androgen synthesis enzymes, in male rats – an androgen-synthesis model that largely reflects this pathway in humans. Orteronel inhibited 17,20-lyase activity in rats with an IC50 of 1200 nM but did not inhibit 17α-hydroxylase or 11β-hydroxylase (CYP11B1) activity in rats at concentrations up to 10 μM. In cellular steroidogenesis assays using rat testicular cells, orteronel suppressed testosterone and androstenedione production with an IC50 of 640 nM and 210 nM, respectively, but did not suppress either corticosterone or aldosterone production in rat adrenal cells at concentrations up to 30 μM. In addition, serum testosterone and androstenedione levels in human chorionic gonadotropin-injected hypophysectomized rats were significantly reduced by single oral administration of orteronel at a dose of 30 mg/kg (both p ≤ 0.01); serum corticosterone and aldosterone levels in ACTH-injected hypophysectomized rats did not result in significant differences compared with controls, following orteronel administration at doses up to 300 mg/kg. Serum testosterone levels in intact male rats were significantly reduced by orteronel 4 h after dosing at 100 mg/kg (p ≤ 0.01); testosterone levels showed a tendency to recover afterward. In intact male rats, the weight of the prostate glands and seminal vesicles was decreased in a dose-dependent manner following multiple doses of orteronel at 37.5, 150, and 600 mg/kg, TID for 4 days. The reversibility of orteronel was further confirmed using a human adrenocortical tumor cell line. In summary, orteronel is a selective and reversible 17,20-lyase inhibitor, and decreases the weight of androgen-dependent organs in male rats. Our data suggests that orteronel would therefore be effective for androgen-dependent disorders such as PC." @default.
• W2068086148 created "2016-06-24" @default.
• W2068086148 creator A5052490297 @default.
• W2068086148 creator A5053799847 @default.
• W2068086148 creator A5071356768 @default.
• W2068086148 creator A5075211314 @default.
• W2068086148 creator A5080391395 @default.
• W2068086148 creator A5086145033 @default.
• W2068086148 creator A5091332840 @default.
• W2068086148 date "2013-03-01" @default.
• W2068086148 modified "2023-10-18" @default.
• W2068086148 title "Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats" @default.
• W2068086148 cites W1570978364 @default.
• W2068086148 cites W1580057573 @default.
• W2068086148 cites W1969978986 @default.
• W2068086148 cites W1993808852 @default.
• W2068086148 cites W2006643930 @default.
• W2068086148 cites W2027081726 @default.
• W2068086148 cites W2035036227 @default.
• W2068086148 cites W2038911580 @default.
• W2068086148 cites W2041880296 @default.
• W2068086148 cites W2052182372 @default.
• W2068086148 cites W2063650987 @default.
• W2068086148 cites W2064293531 @default.
• W2068086148 cites W2066086539 @default.
• W2068086148 cites W2074649788 @default.
• W2068086148 cites W2085540431 @default.
• W2068086148 cites W2095950698 @default.
• W2068086148 cites W2110171529 @default.
• W2068086148 cites W2110534364 @default.
• W2068086148 cites W2121454126 @default.
• W2068086148 cites W2137996608 @default.
• W2068086148 cites W2141569270 @default.
• W2068086148 cites W2152396694 @default.
• W2068086148 cites W2160644239 @default.
• W2068086148 cites W2161459474 @default.
• W2068086148 cites W2165539951 @default.
• W2068086148 doi "https://doi.org/10.1016/j.jsbmb.2012.10.020" @default.
• W2068086148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23146910" @default.
• W2068086148 hasPublicationYear "2013" @default.
• W2068086148 type Work @default.
• W2068086148 sameAs 2068086148 @default.
• W2068086148 citedByCount "31" @default.
• W2068086148 countsByYear W20680861482013 @default.
• W2068086148 countsByYear W20680861482014 @default.
• W2068086148 countsByYear W20680861482015 @default.
• W2068086148 countsByYear W20680861482016 @default.
• W2068086148 countsByYear W20680861482017 @default.
• W2068086148 countsByYear W20680861482018 @default.
• W2068086148 countsByYear W20680861482020 @default.
• W2068086148 countsByYear W20680861482021 @default.
• W2068086148 countsByYear W20680861482022 @default.
• W2068086148 countsByYear W20680861482023 @default.
• W2068086148 crossrefType "journal-article" @default.
• W2068086148 hasAuthorship W2068086148A5052490297 @default.
• W2068086148 hasAuthorship W2068086148A5053799847 @default.
• W2068086148 hasAuthorship W2068086148A5071356768 @default.
• W2068086148 hasAuthorship W2068086148A5075211314 @default.
• W2068086148 hasAuthorship W2068086148A5080391395 @default.
• W2068086148 hasAuthorship W2068086148A5086145033 @default.
• W2068086148 hasAuthorship W2068086148A5091332840 @default.
• W2068086148 hasConcept C121207290 @default.
• W2068086148 hasConcept C126322002 @default.
• W2068086148 hasConcept C134018914 @default.
• W2068086148 hasConcept C185592680 @default.
• W2068086148 hasConcept C2776683971 @default.
• W2068086148 hasConcept C2777911890 @default.
• W2068086148 hasConcept C2778525890 @default.
• W2068086148 hasConcept C2779279991 @default.
• W2068086148 hasConcept C2780352252 @default.
• W2068086148 hasConcept C71315377 @default.
• W2068086148 hasConcept C71924100 @default.
• W2068086148 hasConceptScore W2068086148C121207290 @default.
• W2068086148 hasConceptScore W2068086148C126322002 @default.
• W2068086148 hasConceptScore W2068086148C134018914 @default.
• W2068086148 hasConceptScore W2068086148C185592680 @default.
• W2068086148 hasConceptScore W2068086148C2776683971 @default.
• W2068086148 hasConceptScore W2068086148C2777911890 @default.
• W2068086148 hasConceptScore W2068086148C2778525890 @default.
• W2068086148 hasConceptScore W2068086148C2779279991 @default.
• W2068086148 hasConceptScore W2068086148C2780352252 @default.
• W2068086148 hasConceptScore W2068086148C71315377 @default.
• W2068086148 hasConceptScore W2068086148C71924100 @default.
• W2068086148 hasLocation W20680861481 @default.
• W2068086148 hasLocation W20680861482 @default.
• W2068086148 hasOpenAccess W2068086148 @default.
• W2068086148 hasPrimaryLocation W20680861481 @default.
• W2068086148 hasRelatedWork W1967659878 @default.
• W2068086148 hasRelatedWork W1978423642 @default.
• W2068086148 hasRelatedWork W1986311037 @default.
• W2068086148 hasRelatedWork W1987272049 @default.
• W2068086148 hasRelatedWork W2037685764 @default.
• W2068086148 hasRelatedWork W2053247908 @default.
• W2068086148 hasRelatedWork W2056500036 @default.
• W2068086148 hasRelatedWork W2060319810 @default.
• W2068086148 hasRelatedWork W2067172377 @default.
• W2068086148 hasRelatedWork W2089368232 @default.
• W2068086148 hasVolume "134" @default.

• next